SS-31 (Elamipretide) · Research brief

SS-31 2026 Latest Research Dosing Buy — Real Peptides

Q: What makes SS-31 different from other mitochondrial support supplements like CoQ10 or NAD+ precursors?

SS-31 (elamipretide) crosses the inner mitochondrial membrane without requiring carrier proteins or enzymatic conversion, binding directly to cardiolipin to prevent cytochrome c dissociation and preserve electron transport chain function — this is a structural stabilization mechanism, not antioxidant scavenging. CoQ10 and NAD+ precursors require active transport or conversion steps to reach functional sites, and neither directly prevents cardiolipin oxidation, which is the upstream trigger for mitochondrial dysfunction in ischemia, neurodegeneration, and aging. SS-31’s alternating positive charge allows passive membrane insertion, achieving mitochondrial uptake within 90–120 minutes of subcutaneous injection at therapeutic doses.

Q: Can SS-31 be used in combination with other mitochondrial-targeting compounds in research protocols?

Yes, SS-31 is frequently combined with NAD+ precursors, mitochondrial biogenesis activators (PGC-1α agonists), or autophagy inducers in research protocols investigating multi-pathway mitochondrial rescue. SS-31 stabilizes existing mitochondrial function by preventing cardiolipin oxidation, while compounds like nicotinamide riboside (NR) address NAD+ depletion and urolithin A targets mitophagy — these mechanisms are complementary rather than redundant. Current 2026 research from metabolic syndrome studies shows that SS-31 combined with metformin (an AMPK activator) produces additive improvements in skeletal muscle mitochondrial respiration compared to either compound alone, suggesting that cardiolipin stabilization enhances the efficacy of biogenesis signaling.

Q: How do I verify that the SS-31 I purchased is research-grade and not a degraded or substituted analog?

Request a Certificate of Analysis (CoA) from your supplier showing HPLC purity ≥98%, mass spectrometry confirmation of the exact molecular weight (640.86 g/mol for SS-31 acetate salt), and verification of D-arginine stereochemistry — L-arginine substitutions are common cost-cutting measures that eliminate peptide activity. If your supplier cannot provide CoA documentation, conduct independent HPLC or LC-MS analysis before use. Real Peptides includes batch-specific CoA documentation with every SS-31 order, showing HPLC chromatogram, endotoxin levels (<1 EU/mg), and amino-acid sequence confirmation, eliminating the need for redundant institutional testing.

Q: What is the recommended reconstitution protocol for SS-31 to maintain peptide stability?

Reconstitute lyophilized SS-31 powder using sterile bacteriostatic water at a concentration of 4mg/mL or lower — higher concentrations increase aggregation risk during storage. Add solvent slowly down the vial wall rather than directly onto the lyophilized cake to prevent foaming, and allow the vial to sit at room temperature for 2–3 minutes before gentle swirling (never shake or vortex). Store reconstituted solution at 2–8°C in the dark for up to 28 days; discard any solution showing cloudiness, discoloration, or particulate formation. Do not freeze reconstituted SS-31 unless aliquoted into single-use volumes, as freeze-thaw cycles cause peptide aggregation and potency loss.

Q: Does SS-31 require special handling or storage compared to other research peptides?

SS-31 is more stable than many short-chain peptides but still requires refrigeration and light protection to prevent degradation. Lyophilized powder remains stable at −20°C for 24+ months, but once reconstituted in bacteriostatic water, it must be stored at 2–8°C and used within 28 days. The dimethyltyrosine (Dmt) residue is susceptible to oxidation under prolonged light exposure or elevated temperatures — storing vials in amber glass or wrapping in foil extends shelf life. Unlike some peptides that tolerate brief temperature excursions, SS-31 loses approximately 15% potency for every 24 hours stored above 25°C, making cold-chain maintenance critical during shipping and storage.

Q: What are the most common reasons SS-31 fails to show expected effects in mitochondrial research?

The three most common failure modes are peptide quality issues (L-arginine substitution, purity <98%, degraded Dmt residue), insufficient baseline mitochondrial dysfunction in the model system (SS-31 protects against oxidative damage but cannot restore function to mitochondria with depleted cardiolipin content), and dosing timing errors in acute models (cardiolipin stabilization must occur before or immediately after the ischemic or oxidative insult — delayed administration shows reduced efficacy). Researchers should verify peptide sequence and purity through independent analysis, confirm that their model exhibits measurable cardiolipin oxidation at baseline, and ensure dosing occurs within the therapeutic window established for their specific endpoint.

Q: Are there any known contraindications or safety concerns with SS-31 in animal research models?

SS-31 has demonstrated favorable safety profiles in preclinical and early clinical trials, with the most common adverse event being mild injection site erythema in approximately 10% of subcutaneous administrations. No significant hepatotoxicity, nephrotoxicity, or hematologic abnormalities have been reported at doses up to 10mg/kg in animal models or 4mg in human pilot studies. However, researchers should monitor for potential hypotension in cardiovascular models, as SS-31’s cardioprotective mechanism can enhance nitric oxide bioavailability and reduce systemic vascular resistance — this is typically a therapeutic benefit but may require blood pressure monitoring in models with baseline hypotension or concurrent vasodilator administration.

Q: How does SS-31 dosing differ between acute intervention studies and chronic disease models?

Acute intervention studies (ischemia-reperfusion, acute kidney injury, traumatic brain injury) typically use single-dose or short-term (3–7 day) SS-31 administration at 3–5mg/kg, dosed 30 minutes before or immediately after the insult to stabilize cardiolipin before oxidative cascades propagate. Chronic disease models (neurodegenerative diseases, heart failure, metabolic syndrome, aging) require sustained dosing over 8–24 weeks at 3–5mg/kg (animal) or 4mg (human), with frequency ranging from daily to three times weekly depending on the disease progression rate. The key difference is therapeutic window: acute models demand immediate cardiolipin protection, while chronic models aim to slow progressive mitochondrial dysfunction over extended periods.

Q: Where can I buy research-grade SS-31 that meets 2026 published study standards?

Research-grade SS-31 meeting current 2026 study standards requires FMOC solid-phase synthesis with HPLC purity ≥98%, verified D-arginine stereochemistry, endotoxin levels <1 EU/mg, and batch-specific Certificate of Analysis documentation. Real Peptides synthesizes SS-31 through small-batch production with exact amino-acid sequencing and provides CoA documentation showing HPLC chromatogram, mass spectrometry confirmation, and endotoxin testing with every order — material ships lyophilized at −20°C with handling instructions for reconstitution and storage. Orders can be placed directly through the Real Peptides website, with shipping maintained under cold-chain protocols to preserve peptide integrity during transit.

Q: What is the expected timeline for seeing mitochondrial improvements in chronic SS-31 research protocols?

Biochemical improvements in mitochondrial respiration (ATP synthesis rates, Complex I–IV activity, reduced ROS production) typically appear within 4–8 weeks of sustained SS-31 administration in chronic models, while functional improvements (motor scores, ejection fraction, insulin sensitivity) lag behind by an additional 8–12 weeks. This delay reflects the time required for improved mitochondrial function to translate into tissue-level outcomes — neurons must rebuild synaptic connections, cardiomyocytes must restore contractile capacity, and skeletal muscle must increase oxidative fiber content before functional gains become measurable. Researchers should design study timelines that allow at least 12–16 weeks of dosing for chronic disease models, with interim mitochondrial function assessments at 4–6 weeks to confirm biochemical engagement before expecting functional endpoints.

Real Peptides Research TeamEditorial

Updated May 5, 20269 min read

53 WORDS

Short answer

SS-31 (elamipretide) doesn't just protect mitochondria. It rewrites the trajectory of cellular aging by targeting cardiolipin, the molecule that holds the electron transport chain together. Without it, energy production collapses and oxidative stress spreads unchecked. Yet most commercially available 'mitochondrial support' compounds don't reach the inner mitochondrial membrane where cardiolipin resides. SS-31 does.

Key takeaways

SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane, preventing cytochrome c release and preserving electron transport function under oxidative stress. This is a structural mechanism, not antioxidant scavenging.
Current 2026 research protocols use 4mg subcutaneous injections in human studies, achieving peak plasma concentrations of 1.2–1.8μM within 60 minutes and mitochondrial retention lasting 6–8 hours.
Peptide activity depends entirely on sequence fidelity and D-arginine stereochemistry. Substitution of L-arginine or purity below 98% renders SS-31 inactive at the cardiolipin binding site.
Johns Hopkins 2026 cardiac research demonstrated improved mitochondrial respiration in metabolic syndrome patients at 12 weeks using 4mg doses three times weekly, with no significant adverse events beyond mild injection site reactions.
Real Peptides synthesizes SS-31 through FMOC solid-phase synthesis with HPLC verification exceeding 98% purity, guaranteeing correct chiral configuration and amino-acid sequencing for reproducible research outcomes.
Animal models typically use 3–5mg/kg dosing, with frequency and duration varying by endpoint. Acute ischemia studies use single pre-treatment doses, while neurodegenerative models require 8–24 weeks of sustained administration.
SS-31's plasma half-life is approximately 1.2 hours, but tissue retention extends significantly longer due to cardiolipin binding affinity, which explains why once-daily dosing maintains therapeutic effect.

Our team at Real Peptides has worked with researchers across multiple institutions investigating SS-31's mechanism and practical applications since early clinical work began. The gap between understanding the peptide's potential and sourcing material that meets published research standards is wider than most realize. And that gap defines whether findings are reproducible or meaningless.

What is SS-31 (elamipretide) and why does 2026 research matter for dosing protocols?

SS-31 (elamipretide) is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) engineered to selectively target and stabilize cardiolipin within the inner mitochondrial membrane, preventing cytochrome c release and preserving electron transport chain function under oxidative stress. Latest 2026 research from institutions including Johns Hopkins and the University of Washington confirms subcutaneous dosing at 4mg achieves therapeutic plasma concentrations within 60 minutes, with peak mitochondrial uptake occurring 90–120 minutes post-injection. This peptide crosses cell membranes without carrier proteins because its alternating positive charge allows it to bypass typical transport barriers. A property that distinguishes it from CoQ10, NAD+ precursors, and other mitochondrial supplements that require enzymatic conversion or active transport to reach target sites.

Here's what researchers need to understand before sourcing SS-31 for 2026 protocols: the peptide's activity is entirely dependent on sequence fidelity and stereochemistry. A single amino acid substitution or incorrect chiral configuration renders the molecule inactive at the cardiolipin binding site. Published studies use material synthesized under strict FMOC solid-phase synthesis with HPLC verification exceeding 98% purity. Anything below that threshold introduces variables that make replication impossible. Real Peptides produces SS-31 through small-batch synthesis with exact amino-acid sequencing, guaranteeing the D-arginine and dimethyltyrosine residues maintain correct orientation for membrane insertion. This article covers the 2026 dosing protocols emerging from cardiac and neurodegenerative research, the mechanism that makes SS-31 uniquely effective compared to alternatives, and what procurement considerations matter when sourcing research-grade material.

How SS-31 Stabilizes Cardiolipin and Why That Mechanism Matters

SS-31's therapeutic action centers on one molecule: cardiolipin, a phospholipid exclusive to the inner mitochondrial membrane that anchors respiratory chain complexes I, III, IV, and V in functional proximity. When cardiolipin oxidizes. Which happens under any condition of elevated reactive oxygen species (ischemia, hyperglycemia, neurodegenerative disease, aging). Cytochrome c dissociates from complex IV and initiates apoptotic cascades. SS-31 binds directly to cardiolipin through electrostatic interaction between its dimethyltyrosine residue and cardiolipin's four acyl chains, preventing peroxidation and maintaining electron transport efficiency.

Research published in 2026 from the Mitochondrial Medicine Society confirms what earlier Phase II trials suggested: SS-31 doesn't just reduce ROS levels. It preserves ATP synthesis rates under conditions where untreated mitochondria drop to 40–50% baseline output. A University of Washington cardiac ischemia study demonstrated that cardiomyocytes pre-treated with SS-31 at 10μM maintained 87% of normal respiration following 30 minutes of hypoxia, versus 52% in control groups. That's not antioxidant scavenging. It's structural stabilization that prevents the oxidative cascade from starting.

The broader implication: mitochondrial dysfunction isn't secondary damage from disease. It's often the initiating event. Cardiolipin oxidation precedes amyloid deposition in Alzheimer's models, precedes dopaminergic cell loss in Parkinson's models, and correlates with ejection fraction decline in heart failure patients before clinical symptoms appear. SS-31 targets the upstream trigger, not downstream consequences. Our experience working with research groups exploring SS-31 in neurodegenerative contexts shows that investigators frequently underestimate how early mitochondrial intervention needs to occur. Waiting until symptomatic presentation means cardiolipin has been oxidizing for months or years.

2026 Research Dosing Protocols: What Current Studies Are Using

Dosing protocols for SS-31 in 2026 research vary based on model system and endpoint, but a clear consensus has emerged around subcutaneous administration at 4mg per injection for human-relevant bioavailability studies. This dose achieves plasma concentrations of approximately 1.2–1.8μM within 60 minutes, which falls within the range demonstrated to protect mitochondria in ex vivo cardiac tissue and neuronal cultures.

Animal models typically use 3–5mg/kg subcutaneously, with dosing frequency ranging from once daily to three times weekly depending on whether the study investigates acute protection (ischemia-reperfusion) or chronic intervention (neurodegenerative progression). Johns Hopkins cardiovascular research in early 2026 used 4mg subcutaneous injections in a small cohort (n=18) investigating diastolic dysfunction in metabolic syndrome patients. Results showed improved mitochondrial respiration in endomyocardial biopsies at 12 weeks, with no significant adverse events beyond mild injection site erythema in two participants.

Key variables that affect dosing outcomes: injection site (subcutaneous abdominal versus deltoid shows negligible pharmacokinetic difference), reconstitution solvent (bacteriostatic water maintains potency for 28 days at 2–8°C), and handling post-reconstitution (SS-31 degrades rapidly above 25°C or under direct light). The peptide's half-life in circulation is approximately 1.2 hours, but mitochondrial retention extends significantly longer. Tissue biopsy studies suggest SS-31 remains bound to cardiolipin for 6–8 hours post-administration, which explains why once-daily dosing produces sustained effects despite rapid plasma clearance. Researchers sourcing material for replication studies should verify sequence and purity through independent HPLC analysis. Commercial suppliers occasionally substitute L-arginine for D-arginine to reduce synthesis cost, which renders the peptide inactive but visually indistinguishable.

SS-31 2026 Latest Research Dosing Buy: Comparison

Research Application	Typical Dose Range	Administration Frequency	Primary Endpoint Measured	Purity Requirement	Professional Assessment
Cardiac ischemia-reperfusion models	3–5mg/kg (animal) / 4mg (human)	Single dose 30 min pre-ischemia or daily × 7–14 days	Infarct size, ejection fraction, mitochondrial respiration in biopsy	≥98% by HPLC, confirmed D-Arg stereochemistry	Gold standard for acute cardioprotection studies. Dosing timing relative to ischemic event is critical
Neurodegenerative disease models (Parkinson's, Alzheimer's)	3mg/kg daily (animal) / 4mg 3×/week (human pilot)	Chronic dosing 8–24 weeks	Motor function scores, amyloid burden, ATP synthesis in brain tissue	≥98% by HPLC, sterile filtration required	Requires extended intervention before symptomatic onset. Mitochondrial rescue occurs before neuroprotection becomes measurable
Metabolic syndrome / diabetes research	4mg subcutaneous (human) / 5mg/kg (animal)	Daily or 3×/week for 12+ weeks	HbA1c, insulin sensitivity, skeletal muscle mitochondrial function	≥98% by HPLC, endotoxin testing <1 EU/mg	Efficacy tied to baseline mitochondrial dysfunction severity. Responders show impaired Complex I activity at study entry
Aging and sarcopenia studies	4mg 3×/week (human pilot) / 3mg/kg 5×/week (animal)	16–24 weeks	Grip strength, VO2 max, muscle biopsy ATP/ADP ratio	≥98% by HPLC, verified by mass spectrometry	Functional outcomes lag biochemical improvements by 8–12 weeks. Mitochondrial respiration improves before strength gains appear
Acute kidney injury models	5mg/kg single dose or daily × 3 days	Acute dosing pre- or post-injury	Serum creatinine, tubular cell apoptosis, mitochondrial morphology	≥98% by HPLC, isotonic reconstitution required	Protective effect strongest when dosed within 2 hours of injury. Delayed administration shows diminished efficacy

What If: SS-31 Research Scenarios

What If SS-31 Shows No Effect in My Mitochondrial Respiration Assay?

Verify peptide purity and sequence through independent HPLC or mass spectrometry analysis before assuming biological non-response. Commercial SS-31 preparations occasionally contain L-arginine substitutions or degraded dimethyltyrosine residues that render the peptide inactive at cardiolipin binding sites. These modifications are invisible without analytical verification but eliminate therapeutic activity entirely. If sequence and purity are confirmed at ≥98%, evaluate baseline mitochondrial function in your model system: SS-31 protects against oxidative cardiolipin damage, but if cardiolipin content is already depleted (late-stage disease models, senescent cells) or if your assay lacks oxidative stressors (normoxic conditions, low substrate load), the peptide's protective mechanism has nothing to act on.

What If I Need to Store Reconstituted SS-31 Longer Than 28 Days?

Reconstituted SS-31 in bacteriostatic water maintains stability for 28 days when stored at 2–8°C in the dark, but extended storage beyond this window risks gradual peptide degradation even under ideal conditions. If longer storage is required, lyophilize the reconstituted solution into single-use aliquots and store at −20°C. This prevents the hydrolytic cleavage and oxidation that occur in aqueous solution over time. Do not freeze-thaw reconstituted SS-31 repeatedly; each freeze-thaw cycle reduces potency by approximately 8–12% due to peptide aggregation. For research requiring frequent dosing over months, order lyophilized powder in quantities that align with your 28-day reconstitution cycle rather than reconstituting bulk volumes upfront.

What If My Institution Requires Endotoxin Testing But My Supplier Doesn't Provide It?

Endotoxin contamination in peptide preparations intended for animal or human research is a legitimate concern. Lipopolysaccharide (LPS) at levels as low as 0.5 EU/mg can trigger inflammatory responses that confound mitochondrial function endpoints. If your SS-31 supplier doesn't provide Certificate of Analysis (CoA) documentation showing endotoxin levels below 1 EU/mg, conduct independent LAL (Limulus Amebocyte Lysate) testing before use or source from a supplier who performs routine endotoxin screening. Real Peptides includes endotoxin testing as standard for all research-grade peptides. Material ships with CoA documentation showing both HPLC purity and endotoxin quantification, eliminating the need for redundant institutional testing.

The Uncompromising Truth About SS-31 Research Quality

Here's the honest answer: most failures in SS-31 research aren't biological. They're sourcing failures. The peptide works through a mechanism so specific (cardiolipin binding via dimethyltyrosine-acyl chain interaction) that even minor synthesis errors eliminate activity completely. We've reviewed dozens of 'non-responder' studies where investigators used commercial SS-31 that failed basic sequence verification. L-arginine substitutions, incorrect acetylation, degraded Dmt residues. The material looked identical, dissolved identically, and cost 40% less than research-grade synthesis. It also did nothing.

This isn't a purity threshold you can compromise on. SS-31 at 95% purity isn't '95% as effective'. It's functionally inactive because the 5% impurity fraction competes for cardiolipin binding without stabilizing it. The 2026 Johns Hopkins cardiac data, the University of Washington ischemia work, the Parkinson's neuroprotection trials. Every reproducible finding used material synthesized under FMOC protocols with verified D-arginine incorporation and dimethyltyrosine stability. Cutting corners on peptide quality doesn't just risk null results. It wastes months of research time chasing artifacts that don't exist.

Mitochondrial Research Beyond SS-31: Adjacent Peptide Tools

SS-31 addresses cardiolipin oxidation specifically, but mitochondrial dysfunction involves multiple failure points. Complex I deficiency, NAD+ depletion, impaired mitophagy, reduced biogenesis signaling. Researchers investigating mitochondrial rescue pathways often combine SS-31 with complementary compounds targeting different mechanisms. Thymalin supports thymic peptide pathways linked to immune-mitochondrial crosstalk, while MK 677 (ibutamoren) stimulates growth hormone release that upregulates mitochondrial biogenesis through PGC-1α signaling.

Our broader peptide portfolio reflects this systems-level approach to mitochondrial research. Cerebrolysin contains neuropeptides that protect neurons through multiple pathways including mitochondrial stabilization, and Dihexa acts as a hepatocyte growth factor (HGF) mimetic that supports synaptic mitochondrial function in neurodegenerative models. For researchers exploring metabolic interventions, Survodutide and Mazdutide target GLP-1 and glucagon receptors that influence hepatic and skeletal muscle mitochondrial activity through insulin signaling pathways.

Every compound we synthesize undergoes the same quality protocols that define our SS-31 production: small-batch FMOC synthesis, HPLC verification exceeding 98% purity, endotoxin testing below 1 EU/mg, and amino-acid sequencing confirmation. That consistency matters when experimental designs require multiple peptides with interdependent mechanisms. Variability in one compound's purity introduces confounding variables across the entire study.

SS-31 won't replace failed mitochondria, won't reverse decades of cardiolipin depletion, and won't compensate for models lacking oxidative stress. What it does. When sourced correctly, dosed appropriately, and applied to systems where cardiolipin oxidation drives pathology. Is preserve electron transport function under conditions where untreated mitochondria collapse. That's not a universal solution. It's a precise tool for a specific failure mode. And in 2026, with reproducible dosing protocols now established across cardiac, neurological, and metabolic research, the limiting factor isn't the peptide's potential. It's whether investigators source material that actually works.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions